Chairman & CEO of PsyBio Therapeutics, Evan Levine, shares why PsyBio doesn't use magic mushrooms to make psilocybin medicine.
Similar Posts
Interview with James Lanthier, CEO of Mindset Pharma
In our conversation, James goes into detail about Mindset’s new lead drug candidate MSP-1014, when the company expects to take the drug to clinical trials, and why next generation drugs are an important commercial opportunity for anyone looking to invest in the psychedelic sector.
Interview With Steven Huang, DEI Consultant at MAPS and Numinus
Steven’s consultancy company, Millennial HR Design, focuses on the intersection of DEI and psychedelics, where he intends to be a leverage point for the psychedelics industry to better understand their impact on marginalized communities. With nearly 10 years of industry experience, Steven hopes for more diverse and equitable representation in the psychedelic space.
MindMed Patents 18MC? A new Psychedelic ETF? [ Plus more MMED/MMEDF, LOBE, CYBIN & COOL Updates]
In today’s episode of “This Week in Psychedelic Stocks”, we have News on MindMed (MMED / MMEDF/MMQ), Compass Pathways (CMPS), Cybin (CYBN) , Core One Labs ( COOL) & Lobe Sciences (LOBE).
I covered some breaking news on MindMed yesterday in our impromptu episode on the MindMed stock being added to the FTSE so that MMED / MMEDF news is not in this episode. However, this wasn’t the only big news this week. Compass Pathways (CMPS) received not one but 2 new patents and surely, some of you might find this news worth discussing…
We will cover the latest developments in the field writ large.
This means we will cover any stories that affect the all the companies in this field, as well as company specific developments.
Timestamps:
0:00 – Intro
1:18 – New Psychedelic ETF (PSIL)
5:44 – Baltimore decriminalizes the possession of all drugs
6:53 – Hawaii to study the benefits of psilocybin
8:29 – Harvard University to study psychedelics
9:42 – UCSF also decides to study psychedelics
11:24 – MindMed (MMED / MMEDF / MMQ) announced the company’s 2020 End-Year Financial results + link 12:32 on video end year
12:50 – MindMed files F10 File with the SEC ( important step before uplisting to the NASDAQ)
14:11 – MindMed’s 2020 conference call highlights
15:06 – MindMed (MMED) has now filed a patent application for its 18-MC compound
17:04 – Cybin (CYBN / CLXPF) management restructuring
19:40 – Core One Labs (COOL ) stock updates
20:48 – Lobe Sciences ( Lobe) company updates
So that’s it for This Week in Psychedelic Stocks fellow psychedelic investors!
I hope you guys found some value in this and I’ll keep you posted for more changes!
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌
Instagram: @psychedelicinvestor
email: thepsychedelicinvestor@gmail.com
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
https://benzinga.grsm.io/jameshallifa…
https://benzinga.grsm.io/thepsychedel…
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
#MindMed #MMED #MindMedStock
MindMed Near Term CATALYSTS & Nasdaq Debrief [MMED / MNMD]
So what happened with MindMed (MMED / MNMD) on the day on the NASDAQ uplisting? As we all know, MindMed announced on 23rd of April that the MMEDF stock will uplist on NASDAQ on April 27th under ticker MNMD. for MMED : NEO owners, the stock ticker will remain the same, adjusted to US ER.
Ever since, we all speculated on what will happen to the MindMed stock on April 27 and what will be it’s closing price? On April 26th, the stock price rose to near all time highs and a lot of retail investors thought that on the 27th, the run will continue. MindMed’s move to the Nasdaq was to increase the visibility of its stock in hopes of reaching out to a new group of retail and institutional investors.
Unfortunately, the plan didn’t go so well. While MindMed opened at the previous all time high, the stock dropped throughout the day. MindMed, (MNMD) closed today after its first day on the Nasdaq at: $4.02, down 16%,
most probably due to investors who took some profits, which was one of the scenarios in our previous video on MindMed Nasdaq Uplisting price predictions.
So in this video, I’ll share my thoughts on today’s MMED / MNMD stock events and then discuss the near time future catalysts for MindMed.
Timestamps:
0:00 – Intro
1:27 – Thoughts on MindMed (MNMD) first trading day on NASDAQ
6:05 – MindMed catalyst #1 – Atai’s IPO
7:37 – PSIL ETF coming soon
9:58 – Phase 2a results for MindMed’s Project LUCY
11:38 – Project LUCY starting Phase2b in Q4 this year
12:26 – Completion of Phase 1 Trial for Project Layla (18-MC)
13:08 – Completion of Phase 1 LSD Neutralizer Study
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌
Instagram: @psychedelicinvestor
Email: thepsychedelicinvestor@gmail.com
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor
Links to Clinical trials :
https://clinicaltrials.gov/ct2/results?cond=&term=LSD&cntry=&state=&city=&dist=
https://clinicaltrials.gov/ct2/show/NCT03153579?term=LSD&draw=2&rank=5&fbclid=IwAR3fZtlvGX2UAFI0pOkFNANqVpU8ac5pLBTyfwfbd3D4v_1OW61fZLFZGkY
https://clinicaltrials.gov/ct2/show/NCT03604744?term=LSD&draw=2&rank=6&fbclid=IwAR3fZtlvGX2UAFI0pOkFNANqVpU8ac5pLBTyfwfbd3D4v_1OW61fZLFZGkY
https://mindmed.co/wp-content/uploads/2021/04/MindMed-Corporate-Presentation-4.27.2021.pdf
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
#MindMed #MindMedNasdaq #MindMedstock
MindMed ‘s Plan to END the Opioid Epidemic (How MMED / MMEDF Could Make Billions)
It is an unfortunate fact that the world is dealing with a second hidden epidemic: The Opioid Crisis. Luckily, MindMed ( MMED/ MMEDF ) has a solution: 18-MC. This Psychedelic Medicines company, which may soon be uplisted to the Nasdaq, is testing it’s ibogaine derivative to heal those effected by opioid addiction, whether from fentanyl or doctors’ prescriptions. We may have a light at the end of the tunnel, and the Opioid Epidemic may be defeated. This makes MindMed one of the best stocks for 2021. How much could this be worth? Tune in to find out!
Remember to Like, Subscribe, and SMAH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media!
Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
Resources
https://www.cdc.gov/nchs/pressroom/podcasts/20190911/20190911.htm
https://www.ncbi.nlm.nih.gov/books/NBK541390/#:~:text=Morethan2millionpeople,diseasestraumaandsuicide.
https://www.hhs.gov/opioids/about-the-epidemic/opioid-crisis-statistics/index.html#:~:text=In2018anestimated10.3,and808000peopleusedheroin.&text=Appropriateprescribingofopioidsis,andsafetyofMedicarebeneficiaries.
https://www.ccsa.ca/opioids#:~:text=Canadaisinthemidst,publichealthandsafetyconcern.
https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2020.17477
https://www.publichealthontario.ca/-/media/documents/o/2020/opioid-mortality-covid-surveillance-report.pdf?la=en
https://www.camh.ca/en/health-info/mental-illness-and-addiction-index/opioid-addiction
https://www.drugabuse.gov/publications/drugs-brains-behavior-science-addiction/treatment-recovery
https://preprod.drugfree.org/article/relapse-overdose/
https://mindmed.co/psychedelic-inspired/#scroll_section-1
https://americanaddictioncenters.org/meth-treatment/success-rate-for-ibogaine
https://americanaddictioncenters.org/meth-treatment/success-rate-for-ibogaine
https://s3.ca-central-1.amazonaws.com/ibosafe-pdf-resources/Ibogaine/Treating+drug+dependence+with+the+aid+of+ibogaine_a+retrospective+study.pdf
https://americanaddictioncenters.org/meth-treatment/success-rate-for-ibogaine
https://thethirdwave.co/psychedelics/ibogaine/
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4382526/#:~:text=Theantiaddictiondrugibogainecertainlyaffectstheheartand,ibogaine’spotentiallylifethreateningcardiotoxicity.
https://mindmed.co/wp-content/uploads/2020/11/investor-deck.pdf
https://www.ibogainealliance.org/18-mc/
https://mindmed.co/wp-content/uploads/2020/11/investor-deck.pdf
#MindMed #MMED #MMEDF #MindMedNews #OpioidEpidemic #OpioidCrisis #MindMedStock #18MC #18-MC #PsychedelicStocks
Interview With James Hallifax
In this episode of the Psychedelic Spotlight podcast, we feature James Hallifax, Co-Founder of The Psychedelic Investor.